{
    "chemotherapy": {
            "title": "Common Chemotherapy Drugs",
            "description": "Core cytotoxic agents used in leukemia and cancer regimens.",
            "drugs": [
                {
                    "name": "6-Mercaptopurine",
                    "classification": "Antimetabolite",
                    "route": "Oral",
                    "extravasationRisk": "Non-vesicant",
                    "mechanism": ["Purine analog that interferes with DNA and RNA synthesis."],
                    "indications": ["ALL maintenance", "Mercaptopurine-based regimens"],
                    "sideEffects": ["Myelosuppression", "Hepatotoxicity", "GI upset"],
                    "monitoring": ["CBC", "LFTs", "TPMT enzyme activity"],
                    "warnings": ["Avoid with allopurinol unless dose-adjusted", "Dose adjust in hepatic impairment"],
                    "nursingTips": [
                    "Give on an empty stomach.",
                    "Avoid milk within 1–2 hours.",
                    "Monitor jaundice or abdominal pain."
                    ]
                },
                {
                    "name": "Bleomycin",
                    "classification": "Antitumor Antibiotic",
                    "route": "IV, IM, Subcutaneous",
                    "extravasationRisk": "Irritant",
                    "mechanism": ["Induces DNA strand breaks through free-radical formation."],
                    "indications": ["Hodgkin lymphoma", "Testicular cancer"],
                    "sideEffects": ["Pulmonary toxicity", "Fever", "Skin changes"],
                    "monitoring": ["Baseline & periodic PFTs", "Chest symptoms", "Skin assessment"],
                    "warnings": ["High oxygen concentrations increase lung toxicity"],
                    "nursingTips": ["Premedicate if fever-prone", "Report cough or dyspnea immediately"]
                },
                {
                    "name": "Busulfan",
                    "classification": "Alkylating Agent",
                    "route": "Oral or IV infusion",
                    "extravasationRisk": "Non-vesicant",
                    "mechanism": ["Alkylates DNA causing cross-linking and apoptosis."],
                    "indications": ["AML conditioning regimen", "CML (historical use)"],
                    "sideEffects": ["Pulmonary fibrosis", "Seizures", "Myelosuppression"],
                    "monitoring": ["CBC", "Pulmonary exams", "Busulfan levels if ordered"],
                    "warnings": ["May require seizure prophylaxis at high doses"],
                    "nursingTips": ["Monitor lung symptoms", "Ensure anticonvulsant prophylaxis when ordered"]
                },
                {
                    "name": "Cisplatin",
                    "classification": "Platinum Compound",
                    "route": "IV infusion",
                    "extravasationRisk": "Vesicant",
                    "mechanism": ["Causes DNA cross-linking and apoptosis."],
                    "indications": ["Solid tumors", "Lymphomas (selected protocols)"],
                    "sideEffects": ["Nephrotoxicity", "Ototoxicity", "Nausea/vomiting"],
                    "monitoring": ["Renal function", "Electrolytes (Mg, K)", "Hearing tests"],
                    "warnings": ["Requires vigorous hydration", "High emetogenic risk"],
                    "nursingTips": ["Check urine output", "Ensure pre- and post-hydration", "Monitor for tinnitus"]
                },
                {
                    "name": "Cyclophosphamide",
                    "classification": "Alkylating Agent",
                    "route": "IV infusion",
                    "extravasationRisk": "Non-vesicant",
                    "mechanism": ["Alkylates DNA leading to cell death."],
                    "indications": ["ALL", "Lymphomas", "HyperCVAD A"],
                    "sideEffects": ["Hemorrhagic cystitis", "Myelosuppression", "Alopecia"],
                    "monitoring": ["Urine output", "CBC", "Signs of cystitis"],
                    "warnings": ["Use mesna if high dose", "Ensure hydration"],
                    "nursingTips": ["Hydrate before/after dose", "Monitor for hematuria"]
                },
                {
                    "name": "Cytarabine (Ara-C)",
                    "classification": "Antimetabolite",
                    "route": "IV infusion or Subcutaneous",
                    "extravasationRisk": "Irritant",
                    "mechanism": ["Pyrimidine analog inhibiting DNA polymerase."],
                    "indications": ["AML induction/consolidation", "ALL protocols"],
                    "sideEffects": ["Neurotoxicity", "Conjunctivitis", "Myelosuppression"],
                    "monitoring": ["Neuro checks", "Eye symptoms", "CBC"],
                    "warnings": ["High-risk for cerebellar toxicity in elderly or renal impairment"],
                    "nursingTips": ["Use steroid eye drops", "Perform neuro exam before each high dose"]
                },
                {
                    "name": "Daunorubicin",
                    "classification": "Anthracycline",
                    "route": "IV push (central line)",
                    "extravasationRisk": "Vesicant",
                    "mechanism": ["Intercalates DNA and inhibits topoisomerase II."],
                    "indications": ["AML", "ALL", "3+7 regimen"],
                    "sideEffects": ["Cardiotoxicity", "Red urine", "Myelosuppression"],
                    "monitoring": ["Ejection fraction", "ECG", "CBC"],
                    "warnings": ["Strict vesicant precautions"],
                    "nursingTips": ["Use central line only", "Expect red urine for 24–48 hrs"]
                },
                {
                    "name": "Doxorubicin",
                    "classification": "Anthracycline",
                    "route": "IV push (central line)",
                    "extravasationRisk": "Vesicant",
                    "mechanism": ["Intercalates DNA and produces free radicals."],
                    "indications": ["Lymphomas", "ALL", "Solid tumors"],
                    "sideEffects": ["Cardiotoxicity", "Red urine", "Myelosuppression"],
                    "monitoring": ["Ejection fraction", "ECG", "CBC"],
                    "warnings": ["Lifetime max dose limit", "Avoid extravasation"],
                    "nursingTips": ["Give via dedicated central line", "Observe for chest discomfort"]
                },
                {
                    "name": "Etoposide",
                    "classification": "Topoisomerase II Inhibitor",
                    "route": "IV infusion or Oral",
                    "extravasationRisk": "Irritant",
                    "mechanism": ["Blocks topoisomerase II causing DNA breaks."],
                    "indications": ["Lymphomas", "AML protocols"],
                    "sideEffects": ["Hypotension", "Myelosuppression"],
                    "monitoring": ["CBC", "Blood pressure during infusion"],
                    "warnings": ["Avoid rapid IV push"],
                    "nursingTips": ["Use infusion pump", "Monitor BP throughout infusion"]
                },
                {
                    "name": "Ifosfamide",
                    "classification": "Alkylating Agent",
                    "route": "IV infusion",
                    "extravasationRisk": "Non-vesicant",
                    "mechanism": ["DNA alkylation and cross-linking."],
                    "indications": ["Lymphomas", "Solid tumors"],
                    "sideEffects": ["Hemorrhagic cystitis", "CNS toxicity", "Myelosuppression"],
                    "monitoring": ["Mental status", "Urine output", "CBC"],
                    "warnings": ["Always requires mesna"],
                    "nursingTips": ["Ensure hydration", "Observe for confusion or hallucinations"]
                },
                {
                    "name": "Methotrexate",
                    "classification": "Antimetabolite",
                    "route": "IV, Oral, Intrathecal",
                    "extravasationRisk": "Non-vesicant",
                    "mechanism": ["Inhibits dihydrofolate reductase, blocking DNA synthesis."],
                    "indications": ["ALL", "Lymphomas", "CNS prophylaxis"],
                    "sideEffects": ["Mucositis", "Renal toxicity"],
                    "monitoring": ["Renal function", "MTX levels", "CBC"],
                    "warnings": ["Avoid NSAIDs & cotrimoxazole"],
                    "nursingTips": ["Give leucovorin rescue for high-dose MTX"]
                },
                {
                    "name": "Vincristine",
                    "classification": "Vinca Alkaloid",
                    "route": "IV push (NEVER intrathecal)",
                    "extravasationRisk": "Vesicant",
                    "mechanism": ["Inhibits microtubule formation."],
                    "indications": ["ALL", "Lymphomas", "Myeloma regimens"],
                    "sideEffects": ["Peripheral neuropathy", "Constipation"],
                    "monitoring": ["Bowel pattern", "Neuropathy symptoms"],
                    "warnings": ["Fatal if given intrathecally"],
                    "nursingTips": ["Check for foot drop", "Avoid compressing infusion limb"]
                }
            ]
    },

    "targetedTherapy": {
        "title": "Common Targeted and Monoclonal Therapies",
        "description": "Biologic and molecular agents used in leukemia, lymphoma, and solid tumors.",
        "drugs": [
        {
            "name": "Atezolizumab",
            "classification": "PD-L1 Inhibitor (Immunotherapy)",
            "route": "IV infusion",
            "extravasationRisk": "Non-vesicant",
            "mechanism": ["Blocks PD-L1 interaction to enhance T-cell immune response."],
            "indications": ["Lung cancer", "Urothelial cancer", "Immunotherapy combinations"],
            "sideEffects": ["Fatigue", "Colitis", "Dermatitis", "Hepatitis"],
            "monitoring": ["LFTs", "Thyroid function", "Immune-related symptoms"],
            "warnings": ["Hold treatment for grade 3/4 immune toxicities"],
            "nursingTips": [
            "Assess for diarrhea, abdominal pain (colitis).",
            "Monitor liver enzymes closely.",
            "Educate patient about delayed immune side effects."
            ]
        },
        {
            "name": "Bevacizumab",
            "classification": "VEGF Inhibitor (Monoclonal Antibody)",
            "route": "IV infusion",
            "extravasationRisk": "Non-vesicant",
            "mechanism": ["Inhibits VEGF, preventing tumor angiogenesis."],
            "indications": ["Colon cancer", "Ovarian cancer", "Glioblastoma"],
            "sideEffects": ["Hypertension", "Proteinuria", "Delayed wound healing"],
            "monitoring": ["BP", "Urine protein", "Signs of bleeding"],
            "warnings": ["Avoid during active bleeding or recent surgery"],
            "nursingTips": [
            "Check BP before each cycle.",
            "Dipstick urine for proteinuria.",
            "Delay dose if uncontrolled hypertension."
            ]
        },
        {
            "name": "Bortezomib",
            "classification": "Proteasome Inhibitor",
            "route": "IV or Subcutaneous",
            "extravasationRisk": "Irritant",
            "mechanism": ["Blocks proteasome activity leading to apoptosis."],
            "indications": ["Multiple myeloma", "Mantle cell lymphoma"],
            "sideEffects": ["Peripheral neuropathy", "Thrombocytopenia", "Diarrhea"],
            "monitoring": ["CBC", "Neuropathy signs"],
            "warnings": ["Avoid intrathecal administration"],
            "nursingTips": [
            "Rotate SC sites after each dose.",
            "Assess for numbness or tingling.",
            "Administer antiviral prophylaxis (shingles)."
            ]
        },
        {
            "name": "Cetuximab",
            "classification": "EGFR Inhibitor (Monoclonal Antibody)",
            "route": "IV infusion",
            "extravasationRisk": "Irritant",
            "mechanism": ["Targets EGFR to inhibit tumor proliferation."],
            "indications": ["Colorectal cancer", "Head & neck cancers"],
            "sideEffects": ["Acneiform rash", "Infusion reactions", "Hypomagnesemia"],
            "monitoring": ["Electrolytes (Mg)", "Skin changes", "Respiratory status during infusion"],
            "warnings": ["Premedicate before each infusion"],
            "nursingTips": [
            "Skin rash may indicate response—educate patient.",
            "Use sunscreen; photosensitivity risk.",
            "Monitor electrolytes weekly."
            ]
        },
        {
            "name": "Imatinib",
            "classification": "Tyrosine Kinase Inhibitor (TKI)",
            "route": "Oral",
            "extravasationRisk": "Non-vesicant",
            "mechanism": ["Inhibits BCR-ABL tyrosine kinase."],
            "indications": ["CML (first-line)", "Ph+ ALL"],
            "sideEffects": ["Edema", "Muscle cramps", "Nausea"],
            "monitoring": ["CBC", "LFTs", "Fluid retention"],
            "warnings": ["Take with food to reduce GI upset"],
            "nursingTips": [
            "Assess for ankle/eyelid swelling.",
            "Take with a full glass of water and meal.",
            "Monitor LFTs regularly."
            ]
        },
        {
            "name": "Nivolumab",
            "classification": "PD-1 Inhibitor (Immunotherapy)",
            "route": "IV infusion",
            "extravasationRisk": "Non-vesicant",
            "mechanism": ["Blocks PD-1 pathway to restore immune activation."],
            "indications": ["Lymphoma", "Lung cancer", "Melanoma"],
            "sideEffects": ["Immune hepatitis", "Pneumonitis", "Colitis"],
            "monitoring": ["LFTs", "TSH", "Respiratory symptoms"],
            "warnings": ["Interrupt therapy for severe immune toxicity"],
            "nursingTips": [
            "Screen for cough/dyspnea.",
            "Assess bowel habit changes.",
            "Educate about delayed immune effects."
            ]
        },
        {
            "name": "Pembrolizumab",
            "classification": "PD-1 Inhibitor (Immunotherapy)",
            "route": "IV infusion",
            "extravasationRisk": "Non-vesicant",
            "mechanism": ["Enhances anti-tumor immunity by blocking PD-1."],
            "indications": ["Lung cancer", "Melanoma", "Lymphoma"],
            "sideEffects": ["Immune pneumonitis", "Colitis", "Thyroid dysfunction"],
            "monitoring": ["TSH", "LFTs", "Respiratory status"],
            "warnings": ["Stop therapy if life-threatening immune reaction occurs"],
            "nursingTips": [
            "Observe 30–60 min post-infusion.",
            "Report diarrhea >3 episodes/day.",
            "Check thyroid panel every 4–6 weeks."
            ]
        },
        {
            "name": "Rituximab",
            "classification": "CD20 Monoclonal Antibody",
            "route": "IV infusion",
            "extravasationRisk": "Non-vesicant",
            "mechanism": ["Targets CD20 on B-cells leading to depletion."],
            "indications": ["CLL", "NHL", "Autoimmune disorders"],
            "sideEffects": ["Infusion reactions", "Tumor lysis", "Infections"],
            "monitoring": ["Vital signs during infusion", "CBC", "TLS labs"],
            "warnings": ["Severe infusion reactions common during first dose"],
            "nursingTips": [
            "Premedicate with antihistamine + acetaminophen.",
            "Start infusion at slowest rate.",
            "Have emergency medications ready."
            ]
        },
        {
            "name": "Sorafenib",
            "classification": "Multikinase Inhibitor",
            "route": "Oral",
            "extravasationRisk": "Non-vesicant",
            "mechanism": ["Inhibits tumor cell proliferation and angiogenesis."],
            "indications": ["Renal cell cancer", "Liver cancer", "Thyroid cancer"],
            "sideEffects": ["Hand-foot syndrome", "Diarrhea", "Hypertension"],
            "monitoring": ["BP", "Skin integrity", "Electrolytes"],
            "warnings": ["Take on empty stomach"],
            "nursingTips": [
            "Monitor for palm/sole redness or peeling.",
            "Apply urea cream prophylactically.",
            "Check BP before each cycle."
            ]
        },
        {
            "name": "Trastuzumab",
            "classification": "HER2 Monoclonal Antibody",
            "route": "IV infusion",
            "extravasationRisk": "Non-vesicant",
            "mechanism": ["Targets HER2 receptor reducing tumor cell growth."],
            "indications": ["HER2-positive breast cancer", "Gastric cancer"],
            "sideEffects": ["Cardiotoxicity", "Infusion reactions"],
            "monitoring": ["LVEF (Echo)", "ECG", "Vital signs"],
            "warnings": ["Do NOT give with anthracyclines"],
            "nursingTips": [
            "Check EF before starting and every 3 months.",
            "Observe closely during first infusion.",
            "Stop infusion if chest pain or dyspnea occurs."
            ]
        }
        ]
    },

    "supportiveTherapy": {
        "title": "Adjuvant / Supportive Medications",
        "description": "Medications used to prevent or manage chemotherapy-related side effects and complications.",
        "drugs": [
        {
            "name": "Allopurinol",
            "classification": "Xanthine Oxidase Inhibitor",
            "route": "Oral",
            "extravasationRisk": "Non-vesicant",
            "mechanism": ["Reduces uric acid formation by inhibiting xanthine oxidase."],
            "indications": ["Tumor lysis syndrome prevention"],
            "sideEffects": ["Rash", "Nausea", "Elevated LFTs"],
            "monitoring": ["Uric acid levels", "Renal function"],
            "warnings": ["Use cautiously in renal impairment"],
            "nursingTips": [
            "Start before induction chemo if TLS risk is high.",
            "Encourage adequate hydration.",
            "Teach patient to report rash immediately."
            ]
        },
        {
            "name": "Aprepitant / Fosaprepitant",
            "classification": "NK1 Receptor Antagonist",
            "route": "Oral (Aprepitant) or IV (Fosaprepitant)",
            "extravasationRisk": "Non-vesicant",
            "mechanism": ["Blocks NK1 receptors to prevent delayed nausea and vomiting."],
            "indications": ["Highly emetogenic chemotherapy"],
            "sideEffects": ["Fatigue", "Hiccups", "Constipation"],
            "monitoring": ["Drug interactions (CYP3A4)", "Nausea control"],
            "warnings": ["May reduce hormonal contraceptive efficacy"],
            "nursingTips": [
            "Give with 5-HT3 antagonist + steroid.",
            "Monitor for hiccups and fatigue.",
            "Advise backup contraception during therapy."
            ]
        },
        {
            "name": "Dexamethasone",
            "classification": "Corticosteroid",
            "route": "IV or Oral",
            "extravasationRisk": "Non-vesicant",
            "mechanism": ["Reduces inflammation and prevents chemotherapy-induced nausea."],
            "indications": ["Nausea prophylaxis", "Part of chemotherapy regimens"],
            "sideEffects": ["Hyperglycemia", "Insomnia", "Mood changes"],
            "monitoring": ["Blood glucose", "Signs of infection"],
            "warnings": ["Use cautiously in diabetics"],
            "nursingTips": [
            "Best given in the morning to avoid insomnia.",
            "Monitor blood sugars closely.",
            "Avoid abrupt stopping after prolonged use."
            ]
        },
        {
            "name": "Filgrastim (G-CSF)",
            "classification": "Hematopoietic Growth Factor",
            "route": "Subcutaneous",
            "extravasationRisk": "Non-vesicant",
            "mechanism": ["Stimulates neutrophil production and reduces neutropenia duration."],
            "indications": ["Neutropenia prevention or treatment"],
            "sideEffects": ["Bone pain", "Headache"],
            "monitoring": ["CBC / ANC"],
            "warnings": ["Avoid giving 24 hrs before or after chemo"],
            "nursingTips": [
            "Stop when ANC > 1000 for 2 days.",
            "Clarify timing based on chemo day.",
            "Use warm compresses or loratadine for bone pain."
            ]
        },
        {
            "name": "Furosemide",
            "classification": "Loop Diuretic",
            "route": "IV or Oral",
            "extravasationRisk": "Non-vesicant",
            "mechanism": ["Increases renal excretion of sodium and water."],
            "indications": ["Hydration protocols", "Cisplatin nephroprotection"],
            "sideEffects": ["Hypokalemia", "Dehydration", "Hypotension"],
            "monitoring": ["Electrolytes", "Urine output", "Daily weight"],
            "warnings": ["Avoid in severe dehydration"],
            "nursingTips": [
            "Check potassium before giving.",
            "Monitor urine output closely.",
            "Record strict input/output balance."
            ]
        },
        {
            "name": "Leucovorin (Calcium Folinate)",
            "classification": "Folinic Acid Rescue",
            "route": "IV or Oral",
            "extravasationRisk": "Non-vesicant",
            "mechanism": ["Provides reduced folate to protect cells from methotrexate toxicity."],
            "indications": ["High-dose methotrexate rescue"],
            "sideEffects": ["Nausea", "Flushing"],
            "monitoring": ["Methotrexate levels", "Renal function"],
            "warnings": ["Do not confuse with folic acid"],
            "nursingTips": [
            "Administer EXACTLY on schedule.",
            "Adjust rescue based on MTX levels.",
            "Monitor urine pH during high-dose MTX."
            ]
        },
        {
            "name": "Mesna",
            "classification": "Uroprotectant",
            "route": "IV or Oral",
            "extravasationRisk": "Non-vesicant",
            "mechanism": ["Binds acrolein to prevent hemorrhagic cystitis."],
            "indications": ["Ifosfamide", "High-dose cyclophosphamide"],
            "sideEffects": ["Nausea", "Fatigue", "Bad taste"],
            "monitoring": ["Urine output", "Hematuria"],
            "warnings": ["Ensure hydration to reduce bladder irritation"],
            "nursingTips": [
            "Give EXACTLY on the hydration/chemo schedule.",
            "Encourage drinking plenty of water.",
            "Monitor urine color each shift."
            ]
        },
        {
            "name": "Ondansetron",
            "classification": "5-HT3 Antagonist",
            "route": "IV or Oral",
            "extravasationRisk": "Non-vesicant",
            "mechanism": ["Blocks serotonin receptors to reduce nausea."],
            "indications": ["Chemotherapy-induced nausea"],
            "sideEffects": ["Headache", "Constipation", "QT prolongation"],
            "monitoring": ["ECG if cardiac history", "Bowel movements"],
            "warnings": ["Use cautiously with QT-prolonging drugs"],
            "nursingTips": [
            "Give 30 minutes before chemo.",
            "Increase fluids/fiber for constipation.",
            "Consider ECG in high-risk patients."
            ]
        },
        {
            "name": "Palonosetron",
            "classification": "5-HT3 Antagonist",
            "route": "IV infusion",
            "extravasationRisk": "Non-vesicant",
            "mechanism": ["Long-acting serotonin blockade for delayed nausea control."],
            "indications": ["Moderate/high emetogenic chemo"],
            "sideEffects": ["Constipation", "Headache"],
            "monitoring": ["Pain at IV site", "Bowel habits"],
            "warnings": ["Used once per cycle"],
            "nursingTips": [
            "Preferred for delayed nausea.",
            "Give before chemotherapy begins.",
            "Increase fiber to prevent constipation."
            ]
        },
        {
            "name": "Pegfilgrastim",
            "classification": "Long-acting G-CSF",
            "route": "Subcutaneous",
            "extravasationRisk": "Non-vesicant",
            "mechanism": ["Long-acting stimulation of neutrophil production."],
            "indications": ["Neutropenia prevention"],
            "sideEffects": ["Bone pain", "Injection site pain"],
            "monitoring": ["CBC", "Symptoms of splenic enlargement"],
            "warnings": ["Do NOT give within 14 days before next chemo cycle"],
            "nursingTips": [
            "Administer 24 hours after chemotherapy.",
            "Educate about left-upper-quadrant pain (rare splenic issue).",
            "Use loratadine for bone pain if needed."
            ]
        }
        ]
    }

}
